XClose

Early Phase Cancer Trials Programme at UCL and UCLH

Home
Menu

Early Phase Cancer Trials Programme Publications

Publications:

A list of key publications from the Early Phase Cancer Trials Programme at UCL/UCLH

2021: 

SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma
JournalACS Journals - Cancer / Volume 127, Issue 8 / p. 1301 -1310
Date15 Apr 2021

Principal Investigator

Clinical Trial

Dr. Sandra Strauss

ESP1_SARC025 (ESPIRIT)

AuthorsRashmi Chugh, Karla V. Ballman, Lee J. Helman, Shreyaskumar Patel, Jeremy S. Whelan, Brigitte Widemann, Yao Lu, Douglas S. Hawkins, Leo Mascarenhas, John W. Glod, Jiuping Ji, Yiping Zhang, Denise Reinke, Sandra J. Strauss
Link: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33349

 

 

Conference Abstracts

 A list of key abstracts presented at conferences from the Early Phase Cancer Trials Programme at UCL/UCLH

2021: 

866P - ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced (LA) squamous cell carcinoma of the head and neck (HNSCC)
ConferenceESMO Congress 2021
Date16 Sep 2021
Presenter/ Cancer Principal InvestigatorDr. Martin Forster
AuthorsM. Forster, R. Mendes, T. Guerrero Urbano, M. Evans, M. Lei, V. Spanswick, E. Miles, R. Simões, G. Wheeler, S. Forsyth, L. White
Link: ESMO Congress 2021
CT010 - Primary Results of Phase 2 FOENIX-CCA2: The Irreversible FGFR1-4 Inhibitor Futibatinib in Intrahepatic Cholangiocarcinoma (iCCA) with FGFR2 Fusion/Rearrangements
ConferenceAACR Annual Meeting 2021
Date11 Apr 2021
Presenter/ Cancer Principal InvestigatorProf. John Bridgewater
Author(s)Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Chigusa Morizane, Juan W. Valle, Thomas B. Karasic, Thomas A. Abrams, Robin Kate Kelley, Philippe Cassier, Junji Furuse, Heinz-Josef Klümpen, Heung-Moon Chang, Li-Tzong Chen, Yoshito Komatsu, Kunihiro Masuda, Daniel Ahn, Yaohua He, Nital Soni, Karim A. Benhadji, John A. Bridgewater.
Link: AACR Annual Meeting 2021
129 Mosunetuzamab In Combination With Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase IB Study
ConferenceAmerican Society of Haematolog (ASH) Annual Meeting & Exposition 2021
Date11 Dec 2021
Presenter/ Cancer Principal InvestigatorDr. William Townsend
Author(s)Franck Morschhauser, Mark Bishton, Toby A. Eyre, Emmanuel Bachy, Guillaume Cartron, Loïc Ysebaert, Sabela Bobillo, Norma C. Gutierrez, L. Elizabeth Budde, Christopher P. Fox, Andrea Knapp, Manejeh Yaqub, Michael C. Wei, Carol O’Hear, Haocheng Li, Enkhtsetseg Purev, and William Townsend
Link: ASH Annual Meeting and Exposition 2021
162 Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-22-MM-001 Trial
ConferenceAmerican Society of Haematolog (ASH) Annual Meeting & Exposition 2021
Date11 Dec 2021
Presenter/ Cancer Principal InvestigatorDr. Rakesh Popat
Author(s)Sagar Lonial, Rakesh Popat, Cyrille Hulin, Sundar Jagannath, Albert Oriol, Paul G. Richardson, Thierry Facon, Katja Weisel, Jeremy T. Larsen, Monique C. Minnema, Al-Ola Abdallah, Ashraf Z. Badros, Stefan Knop, Edward A. Stadtmauer, Min Chen, Tuong Vi Nguyen, Alpesh Amin, Elisabeth Kueenburg, Teresa Peluso, Niels W.C.J. van de Donk
Link: https://ash.confex.com/ash/2021/webprogram/Paper147704.html
4118 Enrolment and Outcomes of Ethnic Minorities with Multiple Myeloma Treated in UK Myeloma Research Alliance (UK-MRA) Clinical Trials over 18 Years
ConferenceAmerican Society of Haematolog (ASH) Annual Meeting & Exposition 2021
Date13 Dec 2021
Presentation/ Cancer Principal InvestigatorDr. Rakesh Popat
Author(s)Rakesh Popat, Zoe Craig, Faith E Davies, David Cairns, Catherine Olivier, Gareth J. Morgan, Gordon Cook, Graham H Jackson
Link: https://ash.confex.com/ash/2021/webprogram/Paper149148.html
2746 Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?
ConferenceAmerican Society of Haematolog (ASH) Annual Meeting & Exposition 2021
Date12 Dec 2021
Presenter/ Cancer Principal InvestigatorDr. Rakesh Popat
Author(s)Rakesh Popat, Ashraf Z. Badros, Shaji K Kumar, Paula Rodríguez-Otero, Adam D. Cohen, Salomon Manier, Peter M. Voorhees, Francesca Gay, Robert M. Rifkin, Thomas Martin, Ajai Chari, Katja Weisel, Asim V. Farooq, Bennie H. Jeng, Wee Joo Chng, Hans C. Lee, Jesus Berdeja, Vinay Jadhav, Alessandra Tosolini, Laurie Eliason, Antonio Palumbo, Meletios A. Dimopoulos, Sagar Lonial, Suzanne Trudel, Paul G. Richardson, Evangelos Terpos
Link: https://ash.confex.com/ash/2021/webprogram/Paper152681.html
2479 Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study
ConferenceAmerican Society of Haematolog (ASH) Annual Meeting & Exposition 2021
Date12 Dec 2021
Presenter/ Cancer Principal InvestigatorDr. William Townsend
Author(s)Nilanjan Ghosh, William Townsend, Michael Dickinson, Max Topp, Monica Tani, Armando Santoro, Michael Crump, Franck Morschhauser, Steven Le Gouill, Amitkumar Mehta, Anesh Panchal, Chun Wu, Martin Barrett, Kathryn Humphrey, Naseer Qayum, Martin Hutchings
Link: https://ash.confex.com/ash/2021/webprogram/Paper147780.html

 

2020:

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)
ConferenceAmerican Society of Haematolog (ASH) Annual Meeting & Exposition 2020
Date05/11/2020
Presenter/ Cancer Principal InvestigatorDr. Rakesh Popat
Author(s)

Rakesh Popat, Ajay Nooka, Keith Stockerl-Goldstein, Rafat Abonour, Ryan Ramaekers, Amit Khot, Adam Forbes, Cindy Lee, Bradley Augustson, Andrew Spencer, Maria-Victoria Mateos, Bikramjit Chopra, Rachel Rogers, Deborah A Smith, Jacqueline Davidge, Rocio Montes de Oca, Geraldine Ferron-Brady, Anne Yeakey, Mala Talekar, Brandon E. Kremer, Ira Gupta, Hang Quach

Link: ASH Annual Meeting and Exposition 2020
Absract CT129: HyPeR: A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with Pembrolizumab (MK3475) in patients with refractory solid tumors
Conference:AACR Annual Meeting 2020
Date:15/08/2020
Presenter/ Cancer Principal InvestigatorDr. Dionysis Papadatos-Patos
Author(s)Dionysis Papadatos-Pastos; Abhijit Pal; Melek Akay; Malaka Ameratunga; Sanjena Mithra; Joo-Ern Ang; Sofia Levva; Reece Caldwell; Ruth Riisnaes; Mateus Crespo; Wei Yuan; George Seed; Bora Gurel; Ines Figueiredo; Rita Pereira; Susana Miranda; Anna Ferreira; Suzanne Carreira; Claudia Bertan; Chloe Baker; Ricardo Morilla; Robert Brown; Nahal Masrour; Toby Prout; Anna Zachariou; Alison Turner; Mona Parmar; Mark Van de Velde; Ben Jenkins; Christina Yap; Nina Tunariu; Udai Banerji; Juanita Lopez; Anna Minchom; Johann De Bono
Link: AACR Annual Meeting 2020